A retrospective, multicenter cohort study assessing the safety of ABC/3TC/DTG and BIC/TAF/FTC single-tablet regimens in terms of their discontinuation in patients with HIV-1 infection
Latest Information Update: 12 Nov 2020
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 12 Nov 2020 New trial record
- 08 Oct 2020 Results presented at the 15th International Congress on Drug Therapy and HIV Infection